Drug · ALK / ROS1 TKI · ALK / ROS1 TKI · Verified drug
Crizotinib (Xalkori) structure · mechanism
Crizotinib (Xalkori) 2D structure
- Role
- Drug
- Mechanism class
- ALK / ROS1 TKI
- Parent scaffold
- ALK aminopyridine pharmacophore
- Structure source
- Catalog seed (external identifier on file)
- PubChem CID
- 11626560
- ChEMBL ID
- CHEMBL601719
Hand-written analysis
Mechanism
크리조티닙은 ALK/ROS1/MET를 막는 1세대 TKI입니다. EML4-ALK 폐암에서 시작됐지만 뇌전이가 약점이고 L1196M 등 내성이 빨리 뜹니다.
Medicinal chemistry
아미노피리딘 코어입니다. 후세대는 벤조카바졸(알렉티닙)·매크로사이클(로를라티닙)로 이동합니다.
Indication · context
ALK·ROS1 양성 NSCLC의 1세대입니다. 세대가 올라갈수록 뇌·내성 돌연변이가 설계 목표입니다.
SMILES
C[C@@H](OC1=CC(=C(C=C1)CC2=CN=C(N=C2)N)Cl)C3=CN(N=C3)C4CCNCC4Tags
Related compounds
Comparisons · briefs
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.